Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 12Small Cell Lung Carcinoma 5Nonsquamous Non-Small Cell Lung Cancer 2Neoplasms 2Carcinoma 2Advanced Lung Cancer 2Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Squamous NSCLC 1Squamous Cell Non-small Cell Lung Cancer 1Small Cell Lung Cancer Extensive Stage 1SCLC 1Respiratory Tract Diseases 1Resectable Non-small Cell Lung Cancer 1Resectable NSCLC 1Radiation Pneumonitis 1Osteosarcoma 1Non-small Cell Lung Cancer Metastatic 1Non-Squamous Non-Small Cell Lung Cancer 1NSCLC 1Multiple Primary Lung Cancer 1Lung Diseases 1Locally Advanced Non-Small Cell Lung Cancer 1IIIA Stage Non-small Cell Lung Cancer 1High-Risk Resectable NSCLC 1Brain Neoplasms 1Advanced Non-squamous Non-Small-Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Carboplatin 2sintilimab 1Vinorelbine 1Surgical Procedures, Operative 1Protons 1Paclitaxel 1Cisplatin 1Atovaquone 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Non-Small Cell Lung Cancer × sintilimab × Thoracic × Clear all
NCT06837948 2025-02-20

Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Not yet recruiting
160 enrolled
Thoracic

Locally Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡